In order to examine whether fenbendazole has tumor-promoting activity, a total of 70 male Fischer 344 rats were initiated with a single intraperitoneal injection of 100 mg/kg of diethylnitrosamine (DEN) or were given the saline vehicle alone; beginning 1 wk later, rats were given a diet containing 3,600; 1,800; 600; 200; 70; or 0 ppm of fenbendazole for 8 wk. Subgroups of 5 rats each from the DEN+1,800; DEN+0; 1,800; and 0 ppm groups were euthanatized after 1 wk of fenbendazole treatment, and the remaining animals were euthanatized at 8 wk. After 1 wk, relative liver weights (ratios to body weights) were significantly increased in the DEN+1,800 and 1,800 ppm groups, and based on light microscopy, periportal hepatocellular hypertrophy was evident in these groups. After 8 wk, relative liver weights were significantly increased in the groups given &ge;600 ppm with or without DEN initiation. Periportal hepatocellular hypertrophy, characterized by a marked increase in smooth endoplasmic reticulum, was observed in the groups given &ge;600 ppm with or without DEN initiation. Induction of cytochrome P-450 (CYP) 1A2, 2B1, or 4A1 was noted in the fenbendazoletreated groups with or without DEN initiation; that associated with CYP 1A2 was most marked. Positive immunostaining for anti-CYP 1A1/2 or CYP 2B1/2 was observed diffusely in the livers of animals in the DEN+1,800 and DEN+3,600 ppm groups. The numbers and areas of connexin 32 (Cx32)-positive spots per square centimeter in centrilobular hepatocytes were significantly decreased in an almost dose-dependent manner with fenbendazole treatment after DEN initiation. In situ hybridization for Cx32 mRNA revealed a remarkable decrease in its expression in the centrilobular hepatocytes in the DEN+70 ppm group. The numbers of glutathione Stransferase placental-form positive single cells (plus mini foci) were significantly increased in the DEN+1,800 and DEN+3,600 ppm groups. Since those agents that induce CYP 2B1/2 isozymes and reduce Cx32 in centrilobular hepatocytes have been suggested to be liver tumor promoters, the present results indicate that fenbendazole may be a liver tumor promoter.
INTRODUCTION
Fenbendazole [methyl 5-(phenylthio)-2-benzimidazole carbamate] is a thio-substituted benzimidazole derivative that is widely used in veterinary medicine as a broadspectrum anthelmintic drug for ruminants, swine, and equines. Its mode of anthelmintic action involves inhibition of glucose uptake in the parasitic worm and of tubulin polymerization. Fenbendazole has 2 similar congeners : one is febantel, which is a pro-drug that can be converted in vivo by cyclization to fenbendazole, and the other is oxfendazole, which is a major metabolite that is metabolically interconvertible to fenbendazole in vivo (Fig. 1 ). Because of its wide application in meat-producing animals, small amounts of this drug and of its metabolites are sometimes detected as residues in meat and in some other edible tissues from these animals. The Food and Agriculture Organization/World Health Organization Joint Expert Committee on Food Additives (JECFA) has recommended temporary maximum residue limits (MRL), which are the maximum acceptable concentrations of veterinary drug residues in food products for humans (24) . Fenbendazole, febantel, and oxfenda-zole have common metabolic routes, and oxfendazole is the major residue in food-producing animals following administration of these 3 compounds. Therefore, temporary group MRLs are determined, based on the temporary acceptable daily intake (ADI) for the most toxic drug, oxfendazole, to be 0-4 ~g/kg body weight, which is equivalent to a maximum ADI of 240 Rg for a 60-kg human (24) .
In a 123-wk chronic toxicity and carcinogenicity study with an initial in utero phase, in which Charles River caesarean-derived rats were dosed with fenbendazole at dietary levels of 0, 5, 15, 45, or 135 mg/kg/day, there was a slight increase in the incidence of hepatocellular carcinomas in females from the 135 mg/kg group (23) .
However, the JECFA considered that the results for this highest group (135 mg/kg) could not be used for the assessment of the carcinogenicity of fenbendazole because the maximum tolerated in utero dose had been exceeded.
Thus, it was concluded that there was no evidence of carcinogenic activity of fenbendazole (24) . However, the liver tumor-promoting potential of fenbendazole cannot be ruled out, because the incidences of hepatocellular altered foci and hypertrophy were markedly increased in the 45 mg/kg group. Recently it has been reported that there is a &dquo;good&dquo; association between the ability of chemicals to induce the cytochrome P-450 (CYP) 2B 1/2 isozymes and their potential to promote hepatocarcinogenesis. Therefore, strong liver CYP inducers, such as phenobarbital, which causes a marked increase in CYP 2B 1/2 enzymatic activity, are generally considered to be liver tumor promoters (3, 13) . In addition, it has been demonstrated that various types of liver tumor-promoting agents, including peroxisome proliferators and liver CYP inducers, inhibit gap junctional intercellular communication (GJIC) in the rat liver in vivo ( 11 ) . Phenobarbital has also been shown to reversibly decrease the abundance of the GJIC protein connexin 32 (Cx32) in both preneoplastic-altered hepatic foci and in centrilobular hepatocytes in which CYP 2B l/ 2 isozymes are induced (18) . Based on these findings, it has been suggested that agents that induce CYP 2B 1l2 isozymes and that reduce Cx32 in centrilobular hepatocytes are probably all liver tumor promoters (16) . In the present study, we used a modified 2-stage rat liver carcinogenesis model that is widely used for rapid detection of carcinogenic agents (9) in order to investigate whether fenbendazole exerts liver tumor-promoting effects; we did so by examining levels of P-450 isozymes, GJIC, and altered hepatic foci that were positive for glutathione S-transferase placental form (GST-P), a FIG. 2.-Experimental design of this study. Diet containing fenbendazole was given to each group of rats for 8 wk (following 1-wk recovery period after a single intraperitoneal administration of DEN or saline). Five rats each from groups 2, 6, 7, and 10 were euthanatized at week 2, and the rest were euthanatized at week 9. reliable marker enzyme for preneoplastic lesions in rat hepatocarcinogenesis (20) .
MATERIALS AND METHODS
Animal Experiment. Male Fischer 344 rats (4 wk old) were obtained from Charles River Japan, Inc. (Atsugi, Japan) and were housed in polycarbonated cages (5 rats to a cage), with white chips as bedding, in an air-conditioned animal room (room temperature, 23 ± 2°C; relative humidity, 60 ± 5%; lighting cycle, a 12-hr light/dark cycle). Animals that were without any abnormal findings after a 2-wk acclimatization period were selected for the present study. Powdered basal diet (CRF-1, Oriental Yeast Co. Ltd., Tokyo, Japan) and distilled water were provided ad libitum. Fenbendazole (purity more than 99%) was obtained from Hayashi Pure Chemical Ind., Ltd. (Osaka, Japan). Diethylnitrosamine (DEN) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Figure 2 shows the study design. A total of 70 rats was divided into 10 groups; each group consisted of 5 (groups 1, 3, 4, 5, 8, and 9) or 10 (groups 2, 6, 7, and 10) animals. Animals in groups 1 through 6 were initiated with a single intraperitoneal injection of DEN (100 mg/kg), and the others received a single intraperitoneal injection of saline vehicle alone. One week later, these animals began receiving diets containing fenbendazole (they received this diet for 8 wk) at the following concentrations; group 1, 3,600 ppm; groups 2 and 7, 1,800 ppm; groups 3 and 8, 600 ppm; groups 4 and 9, 200 ppm; group 5, 70 ppm; and groups 6 and 10, 0 ppm. The lower 2 doses (70 and 200 ppm) were selected based on the no-observed effect level (15 mg/kg/day) and based on the minimum dose (45 mg/kg/day) reported to induce liver hypertrophy in the previous 123-wk chronic toxicity study (23) , and the dose of 600 ppm corresponded to that of 135 mg/kg/day, at which liver tumors were increased in the same study.
The 5 animals in each of the groups that received DEN+ 1,800 or DEN+0 ppm fenbendazole and in the groups that received 1,800 or 0 ppm without DEN after 1 wk of fenbendazole treatment as well as the animals in all groups after 8 wk were deeply anesthetized with ether and were euthanatized by exsanguination from the abdominal aorta (after measurement of body weights). The animals underwent complete necropsies, and the livers were excised and their weights were recorded. About one-half of the left and right lateral liver lobes and other lobes were immediately frozen by immersion in liquid nitrogen for subsequent western blotting of P-450 isozymes and Cx32 protein, immunohistochemistry of Cx32, and in situ hybridization of Cx32 mRNA. The remaining parts of the left and right lateral lobes were fixed in 10% neutral-buffered formalin for light microscopy. Small portions of the left lobes of 3 animals each from groups that received DEN+ 1,800 or DEN+0 ppm fenbendazole and from groups that received 1,800 or 0 ppm without DEN after 8 wk of fenbendazole treatment were also fixed in 2.5% glutaraldehyde solution for electron microscopic observation.
Western Blot Analysis of CYP Isozymes. The frozen livers from animals in all DEN-initiated groups and from groups that received 600 or 0 ppm without DEN after 8 wk of fenbendazole treatment were homogenized in 3 volumes of 1.15% potassium chloride (KCI), followed by differential centrifugation and resuspension of microsome fractions in 1.15% KC1/20% glycerol. Microsomal proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% polyacrylamide gels, according to the method of Laemmli (12) , and were then electrophoretically transferred to polyvinylidene difluoride membranes. These were first incubated with goat anti-rat CYP IAI/2, 2B1/2, 2E1, 3A2, or 4Al (1:2000; Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan) for 60 min and were then incubated with peroxidase-labeled rabbit anti-goat IgG (H + L) ( 1:4000; BioMakor&copy; bm, Israel) for 30 min, and binding was visualized with a horseradish-peroxidase conjugate substrate kit (Bio-Rad, CA, USA). Specific contents of each CYP isozyme were quantified by densitometry using National Institutes of Health Image software (National Institutes of Health, USA). Their specificities of each anti-CYP isozyme antibody were reported previously (8) . Immunohistochemistry of P-450 Isozymes. Formalinfixed, paraffin-embedded liver tissue from all DEN-initiated groups (after 8 wk of fenbendazole treatment) was sectioned at 4 ~m and was immunohistochemically stained using the labeled streptavidin-biotin-peroxidase complex (LSAB) method for binding of goat anti-rat CYP lAl/2 and 2B1/2 (1:100; Daiichi Pure Chemicals Co., Ltd.) as primary antibodies. All specimens were lightly counterstained with hematoxylin. Cx32 Immunohistochemistry. Frozen liver slices from all DEN-initiated groups (after 8 wk of fenbendazole treatment) were sectioned at 5 jjbm in a cryostat for Cx32immunohistochemical staining. The sections were fixed in acetone at -20°C, dried, and successively incubated with mouse anti-rat Cx32 monoclonal antibody (1:1000, provided by the pharmacological laboratory, Nihon-Shinyaku, Kyoto, Japan) for 1 hr (22) followed by biotinylated rabbit anti-mouse immunoglobulins ( 1:200; DAKO, Kyoto, Japan) for 1 hr and then fluorescent streptavidin Western Blot Analysis of Cx32 Protein. Frozen livers from DEN+600, DEN+70, or DEN+0 ppm groups after 8 wk fenbendazole treatment were prepared for western blot analysis of Cx32 protein by an alkaline extraction protocol, according to the method of Hertzberg (7) . An equal amount of liver tissue was used for preparation of each protein sample. Protein samples were resolved by 10% SDS-PAGE and were transferred onto Immobilon transfer membranes (Millipore, MA, USA). These were first incubated with the mouse anti-rat Cx32 monoclonal antibody ( 1:1000, Nihon-Shinyaku) overnight at 4°C followed by incubation with alkalinephosphatase-conjugated anti-mouse IgG (DAKO) for 30 min and were then visualized with nitro blue tetrazolium chloride/bromochloroindolyl phosphate (NBT/BCIP) (Boehringer Mannheim, Tokyo, Japan). The specific content of Cx32 protein was quantified by densitometry (Molecular Analyst: Bio-Rad, Tokyo, Japan).
In Situ Hybridization of Cx32 mRNA. In situ hybridization using a digoxygenin-labeled cRNA probe for Cx32 mRNA was performed on frozen liver sections from DEN+70 or DEN+0 ppm groups after 8 wk fenbendazole treatment, as described previously (5) . Briefly, 6-)JLm cryosections were fixed in 4% paraformaldehyde/ 0.01 M phosphate-buffered saline, treated with 0.2 N HCI, acetylated with 0.25% acetic anhydrate, treated with 2X saline sodium citrate (SSC), and prehybridized with 50% formamide/2X SSC. After treatment, the sections were hybridized overnight with a cRNA probe at 50°C, incubated with ribonuclease A (Boehringer Mannheim) followed by alkalinephosphatase-conjugated anti-digoxygenin antibody (Boehringer Mannheim), visualized with NBTBCIP, and counterstained with methyl green.
Light Microscopy and GST-P Immunohistochemistry. Formalin-fixed, paraffin-embedded liver tissue from all DEN-initiated or noninitiated groups were sectioned at 4 (JLm and stained with hematoxylin and eosin for microscopic examination.
In addition, immunohistochemical staining using polyclonal antibody against GST-P was applied in order to allow for quantitative evaluation of altered hepatocellular foci (20) . Formalin-fixed, paraffin-embedded liver tissue after 8 wk of fenbendazole treatment was sectioned at 4 m and immunohistochemically stained using the LSAB method for binding of rabbit anti-rat GST-P antibody (1: i 2000; MBL, Nagoya, Japan). All specimens were lightly counterstained with hematoxylin. Numbers of GST-Ppositive single cells and mini foci (consisting of several hepatocytes) were measured using an IPAP image analyzer (Sumika Technoservice) to generate number values per 4 similarly sectioned liver samples. Electron Microscopy. Samples of livers fixed in glutaraldehyde from groups that received DEN+ 1,800 or DEN+0 ppm fenbendazole and from groups that received 1,800 or 0 ppm without DEN after 8 wk treatment were postfixed with 1 % osmium tetraoxide, embedded in Epon 812, cut with an ultramicrotome, and contrasted with uranyl acetate and lead citrate for electron microscopic examination using a JEOL-1200 EX II electron microscope (JEOL, Tokyo, Japan). Statistical Analysis. Differences in quantitative data for body weights, organ weights, P-450 isozymes, Cx32positive spot and area, and numbers of GST-P-positive single cells plus mini foci were analyzed for statistical significance using the Dunnett's 2-tailed test.
RESULTS

Body and Liver Weights
All animals in each group survived to the end of the fenbendazole treatment (Table I ). Statistically significant decreases in body weights were observed in the groups receiving >DEN+600 ppm when compared with the DEN+0 ppm group after 8 wk of fenbendazole treatment. After 1 wk of fenbendazole treatment, animals in the 1,800 ppm groups with or without DEN initiation showed a significant increase in relative liver weights compared with the corresponding controls. After 8 wk of fenbendazole treatment, relative liver weights were significantly increased in the groups given >600 ppm after DEN initiation. In the noninitiated groups, the absolute liver weight was significantly increased in the group given 1,800 ppm, and relative liver weights were significantly increased in the groups given ?600 ppm after 8 wk.
Light and Electron Microscopy Based on light microscopy, periportal hepatocellular hypertrophy with granular cytoplasmic eosinophilia was evident in the livers of the 1,800 ppm group with or without DEN initiation after 1 wk of treatment (Fig. 3 ). Single-cell necrosis was an occasional observation. After 8 wk in the DEN-initiated and noninitiated groups treated with ~600 ppm, periportal hepatocellular hypertrophy with granular cytoplasmic eosinophilia was more evident, and large hepatocytes with 2 nuclei or a large single nu- cleus, single cell necrosis, and mitotic figures were sometimes observed (Fig. 4) .
Electron microscopy revealed a marked increase in smooth endoplasmic reticulum in hepatocytes in the 1,800 ppm groups with and without DEN initiation after 8 wk of treatment (Fig. 5 ).
Western Blot Analysis of CYP Isozymes and P-450 Immunohistochemistry
Western blot analysis of CYP isozymes after 8 wk of fenbendazole treatment revealed remarkable CYP lA2 induction in the groups treated with ~:600 ppm after DEN initiation in a dose-dependent manner (Table II) . CYP 2B 1 was significantly induced in all groups treated with fenbendazole after DEN initiation (Table II ). In addition, CYP 4Al was also induced in the DEN-initiated groups treated with fenbendazole, except in the 200 ppm group (Table II ). In the group given 600 ppm of fenbendazole, CYP 1 A2, 2B 1, and 4A were significantly induced. No remarkable induction of CYP 2B2, 2E1, and 3A2 and no induction of CYP lAl were found in DEN-initiated groups and in the 600 ppm group treated with fenbendazole when compared with the 0 ppm group (data not shown).
Immunohistochemically, CYP 1A1/2 was stained centrilobularly in the 70 to 600 ppm groups and diffusely in the 1,800 and 3,600 ppm groups. CYP 2B 1/2 was stained diffusely in all DEN+fenbendazole treatment groups, and centrilobular hepatocytes stained more strongly than their periportal counterparts. Almost all hypertrophied hepatocytes in the DEN+ 1,800 and DEN+3,600 ppm groups were positive for both CYP 2B 1/2 and lAl/2 (Fig. 6 ). Cx32 Immunohistochemistry, Western Blot Analysis of Cx32 Protein, and Localization of Cx32 mRNA
In the livers of the DEN+0 ppm group animals (after 8 wk of fenbendazole treatment), Cx32 was expressed diffusely in all hepatocytes (Fig. 7 ). The number of Cx32-positive spots per square centimeter was significantly reduced in the centrilobular zone of the livers by the treatment of fenbendazole for 8 wk after DEN initiation, generally in a dose-dependent manner, and the area of Cx32-positive spots was decreased in the DEN+200, DEN+ 1,800, and DEN+3,600 ppm groups (Table III and Fig. 7) .
Western blot analysis of Cx32 protein revealed no significant differences among the DEN+0, DEN+70, and DEN+200 ppm groups (data not shown). In the livers of the DEN+0 ppm group animals after 8 wk of fenbendazole treatment, Cx32 mRNA was expressed in all hepatocytes (Fig. 8 ). However, the expression of Cx32 mRNA in the centrilobular zone was reduced in the livers treated with DEN+70 ppm (Fig. 8 ).
GST-P Immunohistochemistry GST-P-positive focal lesions were observed in all of the DEN-initiated groups and were not observed in groups without DEN initiation. These lesions consisted of single hepatocytes or mini foci of hepatocytes that were strongly positive for the GST-P marker enzyme. The numbers of GST-P-positive single cells plus mini foci were significantly increased in the DEN-initiated groups treated with > 1,800 ppm compared with the DEN+0 ppm group (Table IV) . 
DISCUSSION
In the previous 123-wk chronic toxicity and carcinogenicity study with an initial in utero phase, fenbendazole was given to CD rats at dietary levels of 0, 5, 15, 45, or 135 mg/kg/day. The treatment with fenbendazole resulted in a small increase in the incidence of hepatocellular carcinomas in female rats at 135 mg/kg and in significant increases in the incidences of hepatocellular focal hyperplasia (females at 135 mg/kg) and of altered hepatocellular foci (males at 45 mg/kg and both sexes at 135 mg/ kg) (23) . In addition, significant periportal hepatocellular hypertrophy was seen in both sexes treated with ~ 15 mg/ kg. These results were originally evaluated by a pathology working group that had convened to evaluate the carcinogenicity of fenbendazole. The working group considered that focal hyperplasia and altered hepatocellular foci might be toxic lesions and that hepatocellular hypertrophy appeared to be an adaptive response. Therefore, these lesions were judged to be unrelated to the formation of hepatocellular neoplasms (23) . JECFA reevaluated the data from this carcinogenicity study in rats FIG. 5.-Electron microscopic appearance of a hepatocyte in a rat given diet containing 1,800 ppm of fenbendazole for 8 wk; hepatocyte shows markedly increased smooth endoplasmic reticulum (arrow). X25,000. and confirmed that the mean body weights of both sexes in the highest dose group were more than 40% lower than those of the controls at the beginning of the study; they also confirmed that the rats in the highest dose group showed overt signs of toxicity at that time. Therefore, the conclusion was that the results for this group could not be used for the assessment of carcinogenicity because the maximum tolerated in utero dose had been exceeded (24) . However, it is still unclear why the incidence of altered hepatocellular foci was also significantly increased in males of the sub-high dose (45 mg/kg) group. The question thus arises as to whether fenbendazole has liver tumor-promoting potential.
In the present study, relative liver weights were significantly increased in both DEN-initiated and noninitiated groups treated with fenbendazole, and under the light microscope, periportal hepatocellular hypertrophy was observed in the higher dose groups. The electron microscopic finding of a marked increase in smooth endoplasmic reticulum in the hepatocytes was in line with the induction of CYP 1A2, 2B l, and 4A1. Therefore, these liver changes could be directly attributable to the fenbendazole administration. It has been reported that in rats, oral administration of 25 mg/kg fenbendazole for 9 days and intraperitoneal administration of 10 mg/kg for 5 days resulted in neither a significant increase in the amount of microsomal CYP nor in an elevation in the activities of microsomal benzphetamine-N-demethylase, aniline hy-droxylase, and aminopyrine-N-demethylase, which belong, respectively, to the CYP 2B1/2, 2E1, 2C3 and 2D1 l classes of isozyme activities (1, 2) . These negative results may be due to the short duration of fenbendazole treatment and to the low doses used. We previously reported that oxfendazole, a major metabolite of fenbendazole, has the ability to induce CYP lA and 2B family in rats (15) . Oxfendazole has also been reported to induce CYP lA2 in rabbits (6) .
Recently it has been suggested that a strong association exists between the ability of agents, such as barbiturates, to induce P-450 isozymes and their potential to promote hepatocarcinogenesis (3, 13) . In particular, strong liver enzyme inducers like phenobarbital, which causes CYP 2B 1/2 elevation, are well known to be hepatic tumor promoters (16) . In contrast, the related amobarbital, pentobarbital, and barbituric acid are only weak inducers of CYP 2B 1/2 enzymatic activity and are relatively ineffective promoters of rat hepatocarcinogenesis (4, 19, 21) . The results of the present study would indicate that this chemical may be categorized as a liver tumor promoter of the phenobarbital class, since CYP 2B 1 was induced by both chemicals. However, further studies are necessary, because it is unknown whether chemicals that cause remarkable induction of CYP 1 A2 are to be regarded as liver tumor promoters.
In the present study, the numbers of GST-P-positive single cells and mini foci were significantly increased in the DEN-initiated groups treated with ~1,800 ppm. Since it has been established that nongenotoxic chemicals that cause increases in the number of GST-P-positive foci in 2-stage hepatocarcinogenesis models are likely to be liver tumor promoters (9) , this might explain the tendency for increased hepatic tumors in the carcinogenicity study of fenbendazole (23) . The reason why only GST-P-positive single cells and mini foci rather than GST-P-positive foci were observed in DEN+fenbendazole groups may be due to the short duration of treatment and to weak cell proliferation, since we did not perform partial hepatectomy in the present 2-stage carcinogenesis model.
GJIC is considered to be essential for maintaining tissue homeostasis, and its disruption is believed to play an important role in carcinogenesis (10) . A number of tumor-promoting agents specifically and reversibly inhibit intercellular coupling of cultured cells (14) , and hepatic tumor promoters such as phenobarbital, polychlorinated biphenyl, dichlorodiphenyltrichloroethane, and clofibrate all inhibit GJIC in the rat liver in vivo (11) . In addition, phenobarbital has been shown to reversibly decrease the abundance of the GJIC protein Cx32 in both preneoplastic-altered hepatic foci and centrilobular hepatocytes (18) . The results of the present study, in which numbers of Cx32-positive spots per square centimeter were significantly decreased in centrilobular hepatocytes of rats treated with ~70 ppm, are quite similar to those for phenobarbital reported by Neveu et al (16) . This is further evidence of the liver tumor-promoting potential of fenbendazole.
We could not detect significant differences in Cx32 protein levels between DEN+0 and DEN+70 or DEN+200 ppm groups on western blot analysis. Krutovskikh et al reported that Cx32 protein disappeared from the hepatocyte plasma membrane and accumulated intracytoplasmically in the centrilobular zone of the livers in rats treated with various tumor-promoting agents (11) . Thus, in our study, there is a possibility that a slight decrease of Cx32 protein in the centrilobular zone might have been undetectable, since homogenized whole liver was used for the western blot analysis. Furthermore, Cx32 mRNA was decreased in the centrilobular zone of the rat liver treated with 70 ppm of fenbendazole. It is well known that Cx32 is decreased posttranslationally under hepatocyte proliferation conditions (17) , and both Cx32 protein and its mRNA are decreased by CCl~ treatment (10) . The mechanism responsible for the centrilobular decrease of Cx32-positive spots and mRNA in our present study is unclear. Therefore, further studies are necessary in order to determine the molecular mechanisms that are responsible for centrilobular alterations in Cx32 and P-450 levels as well as their relevance to hepatocarcinogenesis.
Recently we demonstrated that oxfendazole, which is a major metabolite of fenbendazole, has liver tumor-pro- moting potential using a 2-stage liver carcinogenesis model in rats (15) . Induction of the P-450 isozymes was also observed to a greater extent than with fenbendazole.
In addition, hypertrophy of centrilobular hepatocytes and decreased numbers and areas of Cx32-positive spots in the centrilobular zone and increases of GST-P-positive cell and mini foci were noted with lower doses of oxfendazole compared with fenbendazole. On the other hand, hypertrophy of hepatocytes in the fenbendazole group was observed in the periportal area, whereas in the case of oxfendazole, the centrilobular area was involved. Hypertrophied hepatocytes in the periportal areas in the fenbendazole high-dose groups were almost all positive for anti-CYP 2B 1/2 and lAl/2, but some hypertrophied cells showed weak reactions. Thus, there is a possibility that other metabolic enzymes, such as those responsible for phase II detoxification, might be induced by the fenbendazole treatment. Based on the results of the 2 studies, it can be concluded that oxfendazole has much stronger liver tumor-promoting potential than does fenbendazole.
Since the metabolite of fenbendazole has a stronger liver tumor-promoting potential than does its parent compound, special attention should be paid to the drug residues in animal tissues ingested by consumers. 
